KPC Pharmaceuticals, Inc. Class A

KPC Pharmaceuticals, Inc. Class A

SSSE:600422
8.47
CNY
0.00
(0.00%)
-0.36EPS
6.14BMarket Cap
Mar 19Next Earn
KPC Pharmaceuticals, Inc. Class A
SSE:600422
(Shanghai Stock Exchange)

Recent

price

8.47

P/E

ratio

- -

div

yld

2.87%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.89
3.87
4.8
5.51
5.47
6.23
6.47
7.45
9.24
10.66
10.17
10.89
11.02
11.07
11.15
8.64
6.03
Revenue per Share
0.14
0.21
0.29
0.36
0.37
0.53
0.52
0.42
0.44
0.6
0.6
0.67
0.51
0.71
0.86
0.46
-0.38
Basic EPS, GAAP
0.04
0.15
0.14
0.05
0.22
0.34
0.14
0.02
0.18
0.11
0.33
0.02
0.2
0.85
0.97
0.26
- -
Free Cash Flow per Basic Share
0.04
0.09
0.12
0.16
0.18
0.09
0.23
0.21
0.06
0.15
0.24
0.27
0.31
0.19
0.23
0.37
0.24
Dividend per Share
1.17
1.3
1.49
2.58
3.13
4.2
4.51
4.65
5.01
5.51
5.87
6.31
6.57
8.66
6.94
7.08
6.42
Book Value per Share
0.99
1.1
1.06
2.17
2.59
3.69
3.85
3.83
4.12
4.57
5
5.38
5.75
5.81
4.12
4.27
3.61
Tangible Book Value per Share
628
628
628
651
789
789
789
786
769
761
759
758
751
762
754
761
754
Basic Weighted Avg Shares
1,817
2,434
3,016
3,584
4,316
4,916
5,101
5,852
7,102
8,120
7,717
8,254
8,282
8,430
8,401
6,575
4,546
Sales/Revenue/Turnover
7.13
7.35
7.84
8.09
7.9
9.84
7.97
7.54
6.09
6.89
7.06
6.98
7.42
10.56
11.74
5.71
-3.83
Operating Margin (%)
36
36
43
45
70
77
81
95
100
124
151
184
209
209
199
193
- -
Depreciation Expense
86
130
182
232
289
421
407
330
336
454
457
508
383
541
648
350
-285
Net Income, GAAP
15.92
16.95
16.86
16.92
16.65
14.75
14.85
17.81
18.09
14.08
14.49
18.7
19.24
18.27
19.62
11.51
- -
Effective Tax Rate (%)
4.71
5.35
6.03
6.46
6.69
8.56
7.98
5.64
4.72
5.59
5.92
6.15
4.63
6.41
7.71
5.32
-6.28
Profit Margin (%)
403
450
468
1,102
1,046
1,837
2,008
2,018
2,035
2,024
2,411
2,695
2,878
4,283
3,064
3,898
3,446
Working Capital
20
10
22
- -
- -
298
298
339
255
67
168
150
105
152
95
737
708
LT Debt
820
918
1,057
1,879
2,271
3,336
3,612
3,774
3,949
4,334
4,603
4,940
5,143
7,954
6,746
6,941
6,444
Total Equity
11.28
14.76
16.82
14.43
12.98
12.76
9.23
7.97
7.54
9.67
8.96
9.25
6.71
8.58
9.12
4.97
- -
Return on Invested Capital (%)
8.58
12.2
14.44
15.11
12.66
13.53
10.71
8.11
8.02
9.93
9.2
9.46
6.87
6.03
6.89
4.02
- -
Return on Capital (%)
12.22
16.75
20.69
17.18
14.83
15.45
11.86
9.14
8.96
11.33
10.57
11
7.85
9.37
10.97
6.59
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
874
908
770
LT Borrowings
693
690
677
LT Finance Leases
48
37
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
757
757
757
Market Capitalization
8,630
5,912
6,139

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
7,124
6,920
6,559
Cash, Cash Equivalents & STI
1,624
1,711
1,372
Accounts Receivable, Net
3,377
3,043
3,182
Inventories
1,513
1,551
1,404
Total Current Liabilities
3,412
3,553
3,113
Payables & Accruals
- -
- -
- -
ST Debt
874
908
770
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.72%
10.76%
2.89%
Free Cash Flow
194%
210.92%
-72.73%
Net Income, GAAP
1.7%
0.31%
-46%
Sales/Revenue/Turnover
3.62%
-2.6%
-21.74%
Total Cash Common Dividend
34.4%
13.93%
62.31%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,927
1,702
1,903
2,944
8,401
2025
1,608
1,743
- -
1,824
6,575
2026
836
807
1,079
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.15
0.21
0.34
0.86
2025
0.12
0.14
- -
0.11
0.46
2026
-0.19
-0.29
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.21
0.01
0.23
2025
0.01
0.02
- -
0.03
0.37
2026
0.01
0.01
0.19
- -
- -
Business
KPC Pharmaceuticals, Inc., a prominent drug manufacturer, is actively engaged in the research, development, production, and widespread distribution of pharmaceutical products within the People's Republic of China and across international markets. The company specializes in innovative natural botanical medicines, traditional Chinese remedies, and chemical pharmaceuticals, encompassing a broad range of drug circulation activities. Its comprehensive product portfolio features the Artemether series, crucial for malaria treatment, alongside the Panax Notoginseng and Gastrodine series, primarily targeting cardio-cerebral-vascular and nervous system disorders. Brands such as Luotai, Tianxuanqing, Artemedine, Artem, and Arco are well-regarded both domestically and internationally. Beyond these core offerings, KPC Pharmaceuticals also provides ethnic medicines, various antibiotics, essential chemical pharmaceutical raw materials, finished chemical preparations, traditional Chinese medicinal ingredients, biological agents, biochemical drugs, and health food items. The company’s strategic focus extends to chronic disease management and the burgeoning "silver age" health industry, leveraging Yunnan's rich plant resources to develop over 40 natural botanical drugs. Notably, its "777" brand centers on the Panax notoginseng series, and it holds a significant market share in Gastrodin products with the Tianxuanqing brand. KPC also champions artemisinin antimalarials globally, particularly in Africa, overseeing the entire value chain from cultivation to distribution. The enterprise, which originated as Kunming Pharmaceutical Corporation and adopted its current name in April 2015, was established in 1951 and maintains its headquarters in Kunming, China. It was listed on the Shanghai Stock Exchange in 2000 and currently operates numerous subsidiaries, distributing products in over 60 countries.